TRGNF News and Press, Transgene S.A. From 01/06/23

TG6050 is a proprietary oncolytic virus derived from Transgene’s Invir.IO™ platform encoding interleukin-12 (IL-12) and an anti-CTLA4 antibody. The Phase I trial, named Delivir, will evaluate the intravenous (IV) administration of this novel multi-armed immunotherapy in patients...

Regulatory News: TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2023: About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s progr...

Transgene S.A. press release ( OTC:TRGNF ): Q3 revenue of €0.7M (+250.0% Y/Y). Cash, cash equivalents and other financial assets stood at €36.3M as of September 30, 2022, compared to €49.6M as of December 31, 2021. Transgene has financial visibili...

Transgene (OTCPK:TRGNF) says that early results from two phase 1 trials of TG4050, its neoantigen cancer vaccine, indicated clinical activity and anti-tumor cellular immune responses in six patients. The patients treated had ovarian or head and neck cancer. Primary endpoints in the trials wer...

The following slide deck was published by Transgene SA in conjunction with their 2021 Q2 earnings call. For further details see: Transgene SA 2021 Q2 - Results - Earnings Call Presentation

BioInvent International AB (BOVNF) and Transgene (TRGNF) announce that their Investigational New Drug ((IND)) application for BT-001 has been granted by the FDA.This IND will allow patients in U.S. to be enrolled into ongoing Phase 1/2a clinical trial of BT-001, which is evaluating BT-001 as ...

Transgene S.A.  (TRGNF): Q1 Revenue of €2.4M (-20.0% Y/Y)Cash, cash equivalents and other financial assets of €19.1M. Press Release For further details see: Transgene S.A.  reports Q1 results

Transgene ([[TRGNF]]) announces the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors.Transgene has amended the initial Phase Ib/II trial protocol to enable a more rapid start...

BioInvent International AB (BOVNF) and Transgene (TRGNF) have enrolled the first patient in a Phase I/IIa clinical trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). The Phase I will be divided into two parts:Part A will enrol...

Transgene (TRGNF) has received approval in France to proceed with a Phase I/IIa study of the novel oncolytic Vaccinia virus BT-001 developed with Invir.IO platform.This announcement follows approval received in December 2020 in Belgium. The first patient is expected to be enrolled in this tri...